Clinical trials
Breast Cancer Patients clinical trials
Below are recruiting breast cancer patients clinical trials, each written for real people, not researchers. We’re tracking 2,247 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Columbia, MarylandAges 18 years+ - NCT05753618RecruitingPhase 4
Skipping growth-factor shots during breast cancer chemotherapy
This trial tests whether patients can safely skip a preventive white-blood-cell growth shot (G-CSF) while receiving a common breast cancer chemotherapy regimen. It may help reduce injections and side effects, while watching closely for fevers and low white blood counts.
Kingston, OntarioAges 18 years+ - NCT05753657RecruitingEarly Phase 1
Testing insulin and blood sugar monitoring with pioglitazone
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
HaifaAges 18–85 - NCT05760612RecruitingPhase 3
After breast cancer surgery, test neratinib plus trastuzumab
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
GuangzhouAges 18–70 - NCT05762900RecruitingPhase 2
Shorter breast radiation after surgery for low-risk breast cancer
This Phase 2 trial tests a shorter, focused radiation treatment after breast surgery, either alone or with an extra targeted boost. It’s for people with low-risk breast cancer and no spread to distant organs, aiming to keep results while reducing treatment time and side effects.
BeijingAges 35 years+ - NCT05772390RecruitingPhase 2
Second radiation for a small breast cancer return
This Phase 2 study tests whether giving targeted radiation again to the same breast can control a small, local breast cancer that came back after prior whole-breast radiation. It may help some patients avoid or delay further treatment for the breast while carefully checking safety.
Meldola, Forlì CesenaAges 18 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05780814Recruiting
Treating insomnia to improve weight loss after breast cancer
This study looks at whether improving insomnia (trouble falling asleep or staying asleep) can help survivors of breast cancer lose weight more successfully through a structured behavioral weight loss program. It may help if sleep problems are making it harder to change eating and activity habits.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05795101RecruitingPhase 2
TRUDI trial for inflammatory breast cancer with HER2/low markers
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
Boston, MassachusettsAges 18 years+ - NCT05795335Recruiting
Testing CDK4/6 medicines for advanced hormone-positive breast cancer
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05796973RecruitingPhase 3
Exercise and atorvastatin for metastatic cancer outcomes
This trial tests whether a structured exercise program, along with the cholesterol medicine atorvastatin, can improve outcomes in people with metastatic prostate, breast, ovarian, or kidney cancer. It may help by reducing inflammation and supporting physical function during cancer treatment.
Tampere, Länsi-SuomiAges 18–99 - NCT05797454Recruiting
Two ways to mark hidden breast tumors before surgery
This trial compares two techniques for pinpointing non-touchable breast cancer during breast-conserving surgery. The study aims to see which method is more accurate and whether it leads to better surgical outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT05798338Recruiting
Study blood samples and tiny cell particles in breast cancer
This study looks at tiny particles released by cells (called extracellular vesicles) in people with breast cancer. It may help researchers better understand breast cancer and how it behaves, which could improve future testing or treatments.
Pavia, LombardyAges 18–90 - NCT05800275RecruitingPhase 2
Tucatinib and capecitabine plus spinal trastuzumab for HER2+ cancer
This Phase 2 trial tests a combination of tucatinib and capecitabine (taken by mouth) plus trastuzumab delivered into the spinal fluid, to treat breast cancer that has spread to the leptomeninges (lining around the brain/spinal cord). It may help reduce cancer activity in the spinal fluid and improve symptoms.
BordeauxAges 18 years+ - NCT05804916RecruitingPhase 2/Phase 3
Tracking-guided radiation for left breast after surgery
This trial tests a radiation planning and monitoring approach that uses surface tracking and breathing control to deliver large-area radiation more accurately for left breast cancer. It may help improve how consistently treatment is delivered while accounting for chest movement.
Beijing, Beijing MunicipalityAges 18–70 - NCT05817227Recruiting
Study of selenium-related markers in triple-negative breast cancer
This study looks at “selenoproteins” (protein markers in the body) to understand how triple-negative breast cancer behaves and whether they could be targets for future treatments. You may be asked to provide samples before any cancer drug treatment to see if these markers predict outcomes.
Naples, NapoliAges 18 years+ - NCT05833659Recruiting
Comparing two breast reconstruction positions after mastectomy
This trial compares two surgical techniques for breast reconstruction: placing the implant under the chest muscle versus in front of it. It may help people understand which approach works better for comfort and healing after mastectomy.
Beijing, Beijing MunicipalityAges 18–70 - NCT05837455RecruitingPhase 2
Biomarker-guided treatment for early breast cancer before surgery
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
St Louis, MissouriAges 18 years+ - NCT05838001Recruiting
Testing two ways to locate non-tumor-feel breast cancer
This trial compares two techniques for finding breast tumors that cannot be felt by hand after initial (neoadjuvant) treatment. If successful, it may make breast-conserving surgery more accurate when the tumor has become “non-palpable.”
Guangzhou, GuangdongAges 18 years+ - NCT05846789RecruitingPhase 2
Chemotherapy with or without tocilizumab for breast cancer
This Phase 2 trial tests whether adding tocilizumab (a drug that targets inflammation signals) to standard chemotherapy helps people with triple-negative or ER-low metastatic or locally recurring breast cancer. It’s for adults who have had up to two prior treatments for metastatic disease and who can receive standard chemo.
Atlanta, GeorgiaAges 18 years+ - NCT05851014RecruitingPhase 3
GB491 plus letrozole for HR+ HER2- advanced breast cancer
This Phase 3 study tests whether GB491 used together with letrozole works better for hormone receptor–positive and HER2-negative advanced breast cancer. You may be eligible if you have not had certain prior cancer treatments and your health tests are within safe limits.
Bengbu, AnhuiAges 18–75 - NCT05858398Recruiting
How body composition affects chemotherapy results in breast cancer
This study looks at whether body fat and muscle (body composition) change how well certain chemotherapy works after surgery for early breast cancer. You may be considered if you are planned to receive docetaxel as adjuvant (after-surgery) chemotherapy and have recent CT scan images.
RouenAges 18 years+ - NCT05861271RecruitingPhase 2
Adjuvant pyrotinib plus capecitabine for tiny HER2 breast cancer
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05866432RecruitingPhase 2
Dato-DXd for triple-negative breast cancer brain metastases
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
Vienna, State of ViennaAges 18–100
Hear when a new Breast Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer patients?
- Yes. Clin2 currently lists 2,247 recruiting breast cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.